These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 11720611)

  • 1. Cardiovascular safety of non-steroidal anti-inflammatory drugs.
    Nadesalingam K; Kirby D
    Br J Gen Pract; 2013 Dec; 63(617):632. PubMed ID: 24351476
    [No Abstract]   [Full Text] [Related]  

  • 2. l-Carnitine and heart disease.
    Wang ZY; Liu YY; Liu GH; Lu HB; Mao CY
    Life Sci; 2018 Feb; 194():88-97. PubMed ID: 29241711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-carnitine treatment for congestive heart failure--experimental and clinical study.
    Kobayashi A; Masumura Y; Yamazaki N
    Jpn Circ J; 1992 Jan; 56(1):86-94. PubMed ID: 1538579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis.
    DiNicolantonio JJ; Lavie CJ; Fares H; Menezes AR; O'Keefe JH
    Mayo Clin Proc; 2013 Jun; 88(6):544-51. PubMed ID: 23597877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supplementation of L-carnitine in athletes: does it make sense?
    Karlic H; Lohninger A
    Nutrition; 2004; 20(7-8):709-15. PubMed ID: 15212755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RIPK1 blocks T cell senescence mediated by RIPK3 and caspase-8.
    Imanishi T; Unno M; Yoneda N; Motomura Y; Mochizuki M; Sasaki T; Pasparakis M; Saito T
    Sci Adv; 2023 Jan; 9(4):eadd6097. PubMed ID: 36696505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of L-carnitine Supplementation on Circulating C-reactive Protein Levels: A Systematic Review and Meta-Analysis.
    Sahebkar A
    J Med Biochem; 2015 Apr; 34(2):151-159. PubMed ID: 28356827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders.
    Mingorance C; Rodríguez-Rodríguez R; Justo ML; Alvarez de Sotomayor M; Herrera MD
    Vasc Health Risk Manag; 2011; 7():169-76. PubMed ID: 21490942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic potential of carnitine in cardiovascular disorders.
    Pepine CJ
    Clin Ther; 1991; 13(1):2-21; discussion 1. PubMed ID: 2029724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propionyl l-carnitine: intermittent claudication and peripheral arterial disease.
    Andreozzi GM
    Expert Opin Pharmacother; 2009 Nov; 10(16):2697-707. PubMed ID: 19827991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carnitine and its role in cardiovascular disease.
    Retter AS
    Heart Dis; 1999; 1(2):108-13. PubMed ID: 11720611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New thoughts of pathophysiology and therapy of ischemic heart disease.
    Pepine CJ
    Cardiologia; 1991 Dec; 36(12 Suppl 1):373-7. PubMed ID: 1841793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review.
    Ferrari R; Merli E; Cicchitelli G; Mele D; Fucili A; Ceconi C
    Ann N Y Acad Sci; 2004 Nov; 1033():79-91. PubMed ID: 15591005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carnitine and its derivatives in cardiovascular disease.
    Arsenian MA
    Prog Cardiovasc Dis; 1997; 40(3):265-86. PubMed ID: 9406679
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.